A rare immune-mediated enteropathy characterized by chronic diarrhea, malabsorption, small-intestinal villous injury, and immune dysregulation. It can occur as isolated adult disease or as part of monogenic immune dysregulation syndromes such as IPEX and IPEX-like disorders.
Ask a research question about Autoimmune Enteropathy. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Autoimmune Enteropathy
creation_date: "2026-05-07T19:05:50Z"
updated_date: "2026-05-07T19:54:48Z"
category: Autoimmune
parents:
- Autoimmune Disease
- Gastrointestinal Disease
disease_term:
preferred_term: autoimmune enteropathy
term:
id: MONDO:0019787
label: autoimmune enteropathy
description: >
A rare immune-mediated enteropathy characterized by chronic diarrhea,
malabsorption, small-intestinal villous injury, and immune dysregulation.
It can occur as isolated adult disease or as part of monogenic immune
dysregulation syndromes such as IPEX and IPEX-like disorders.
pathophysiology:
- name: FOXP3-Associated Treg Deficiency
description: >
FOXP3-associated IPEX causes impaired regulatory T-cell development and
function, weakening peripheral tolerance and permitting pathogenic
effector-T-cell activity at mucosal surfaces.
cell_types:
- preferred_term: Regulatory T cell
term:
id: CL:0000815
label: regulatory T cell
biological_processes:
- preferred_term: Regulation of T cell activation
term:
id: GO:0050863
label: regulation of T cell activation
evidence:
- reference: PMID:30443250
reference_title: "Clinical, Immunological, and Molecular Heterogeneity of 173 Patients With the Phenotype of Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked (IPEX) Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "(IPEX) Syndrome is a rare recessive disorder caused by mutations in the FOXP3"
explanation: >
The IPEX cohort establishes FOXP3-associated immune dysregulation as a
monogenic context in which enteropathy occurs.
- reference: PMID:30443250
reference_title: "Clinical, Immunological, and Molecular Heterogeneity of 173 Patients With the Phenotype of Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked (IPEX) Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "FOXP3 is the key factor in human Treg development and competitiveness"
explanation: >
Supports the atomic mechanism that FOXP3 disruption impairs the
regulatory T-cell compartment.
downstream:
- target: Mucosal Epithelial Injury
description: >
Loss of FOXP3-dependent regulatory T-cell control permits effector immune
injury to enterocytes and small-intestinal mucosa.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- uncontrolled proliferation of activated CD4+ effector cells
- destruction of epithelial cells by activated CD4 T lymphocytes
evidence:
- reference: PMID:24045285
reference_title: "Abatacept: a new treatment option for refractory adult autoimmune enteropathy."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "destruction of epithelial cells is mediated via activation of CD4 T lymphocytes"
explanation: >
This supports the downstream edge from immune regulatory failure to
epithelial injury.
- name: CTLA4 Checkpoint Dysfunction
description: >
CTLA4 haploinsufficiency causes defective regulatory T-cell checkpoint
function, reducing cell-contact-dependent suppression and producing an
IPEX-like immune-dysregulation phenotype with enteropathy.
cell_types:
- preferred_term: Regulatory T cell
term:
id: CL:0000815
label: regulatory T cell
- preferred_term: T cell
term:
id: CL:0000084
label: T cell
biological_processes:
- preferred_term: Regulation of T cell activation
term:
id: GO:0050863
label: regulation of T cell activation
evidence:
- reference: PMID:30443250
reference_title: "Clinical, Immunological, and Molecular Heterogeneity of 173 Patients With the Phenotype of Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked (IPEX) Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "heterozygous mutation in CTLA4 resulting in CTLA4 haploinsufficiency, causing decreased capacity to mediate cell contact-dependent suppression"
explanation: >
Supports CTLA4 haploinsufficiency as a distinct checkpoint mechanism
impairing regulatory T-cell suppression.
- reference: PMID:30443250
reference_title: "Clinical, Immunological, and Molecular Heterogeneity of 173 Patients With the Phenotype of Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked (IPEX) Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "In patients with CTLA4 deficiency the frequency of CD4+ Treg cells was normal or slightly decreased, suggesting that autoimmunity in these patients is caused by defective Treg function."
explanation: >
Supports that CTLA4-associated disease reflects defective Treg function,
not simply absent Treg cells.
downstream:
- target: Mucosal Epithelial Injury
description: >
CTLA4 checkpoint failure weakens mucosal immune restraint, allowing
immune-mediated enterocyte injury and villous damage.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- reduced cell-contact-dependent suppression
- activated CD4 T lymphocyte-mediated epithelial destruction
evidence:
- reference: PMID:24045285
reference_title: "Abatacept: a new treatment option for refractory adult autoimmune enteropathy."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "destruction of epithelial cells is mediated via activation of CD4 T lymphocytes"
explanation: >
This supports the modeled edge from checkpoint dysfunction to mucosal
epithelial injury.
- name: LRBA-Associated CTLA4 Trafficking Defect
description: >
LRBA deficiency is modeled separately from FOXP3 and primary CTLA4
haploinsufficiency because it affects CTLA4 biology indirectly through
intracellular trafficking and reduced Treg function in IPEX-like disease.
cell_types:
- preferred_term: Regulatory T cell
term:
id: CL:0000815
label: regulatory T cell
biological_processes:
- preferred_term: Regulation of T cell activation
term:
id: GO:0050863
label: regulation of T cell activation
evidence:
- reference: PMID:30443250
reference_title: "Clinical, Immunological, and Molecular Heterogeneity of 173 Patients With the Phenotype of Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked (IPEX) Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "More recently, mutations in LRBA have been reported as a cause of IPEX-like clinical manifestations characterized by early-onset enteropathy and endocrinopathies (35)."
explanation: >
Supports LRBA as an IPEX-like mechanism associated with early-onset
enteropathy.
- reference: PMID:30443250
reference_title: "Clinical, Immunological, and Molecular Heterogeneity of 173 Patients With the Phenotype of Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked (IPEX) Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "FOXP3+Tregs were evaluated in two of four patients with mutations in the LRBA gene. Both patients had a reduction in the percentage of Treg cells"
explanation: >
Supports an LRBA-associated Treg abnormality distinct from FOXP3 primary
transcriptional deficiency.
downstream:
- target: CTLA4 Checkpoint Dysfunction
description: >
LRBA-related Treg abnormalities converge on impaired checkpoint-mediated
immune regulation.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- impaired intracellular CTLA4 trafficking or recycling
- defective Treg function
evidence:
- reference: PMID:30443250
reference_title: "Clinical, Immunological, and Molecular Heterogeneity of 173 Patients With the Phenotype of Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked (IPEX) Syndrome."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: "The progress of DNA sequencing technologies has rapidly expanded the group of IPEX-like disorders caused by mutations in genes coding for proteins involved primarily (i.e., IL2Ra, STAT5b, CTLA4) and secondarily (i.e., LRBA, STAT3-GOF, STAT1-GOF) in Treg generation and function"
explanation: >
The review places LRBA secondarily in the Treg-generation/function
network that includes CTLA4; the trafficking detail is retained as a
mechanistic intermediate from the review comment and deep-research
synthesis rather than overquoted from this cache.
- name: Mucosal Epithelial Injury
description: >
Immune dysregulation converges on small-intestinal mucosal injury with
villous blunting, crypt inflammation, epithelial apoptosis, and loss of
specialized epithelial lineages such as goblet and Paneth cells.
cell_types:
- preferred_term: Intestinal epithelial cell
term:
id: CL:0002563
label: intestinal epithelial cell
biological_processes:
- preferred_term: Apoptotic process
term:
id: GO:0006915
label: apoptotic process
- preferred_term: Inflammatory response
term:
id: GO:0006954
label: inflammatory response
evidence:
- reference: PMID:38817655
reference_title: "Clinical manifestations, diagnosis and long-term prognosis of adult autoimmune enteropathy: Experience from Peking Union Medical College Hospital."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "hyperemia in the duodenum and ileum. Villous blunting (100%), deep crypt"
explanation: >
Adult cohort histology directly supports villous injury, crypt
lymphocytic infiltration, and epithelial apoptosis as core mucosal
pathology.
- reference: PMID:38817655
reference_title: "Clinical manifestations, diagnosis and long-term prognosis of adult autoimmune enteropathy: Experience from Peking Union Medical College Hospital."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "other remarkable abnormalities, including reduced or absent goblet cells"
explanation: >
Supports depletion of intestinal epithelial lineages and inflammatory
injury in adult AIE biopsies.
downstream:
- target: Chronic Diarrhea
description: >
Small-intestinal villous injury and epithelial-lineage loss produce the
chronic diarrhea phenotype that defines AIE.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- villous blunting
- reduced or absent goblet cells
- neutrophilic infiltration
evidence:
- reference: PMID:38817655
reference_title: "Clinical manifestations, diagnosis and long-term prognosis of adult autoimmune enteropathy: Experience from Peking Union Medical College Hospital."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Diarrhea in AIE patients was characterized by secretory diarrhea."
explanation: >
The adult cohort links the mucosal injury context in the same AIE
patients to the diarrhea phenotype.
- target: Malabsorption
description: >
Villous blunting and epithelial injury reduce small-intestinal absorptive
function, producing malabsorption.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
intermediate_mechanisms:
- partial or complete villous blunting
- deep crypt lymphocytosis
- epithelial apoptosis
evidence:
- reference: PMID:24045285
reference_title: "Abatacept: a new treatment option for refractory adult autoimmune enteropathy."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "chronic diarrhea (> 6 weeks duration), (B) malabsorption, (C) small bowel histology showing partial or complete villous blunting"
explanation: >
Diagnostic criteria support the structural edge from small-bowel
histologic injury to malabsorption.
- name: Autoantibody-Associated Enteropathy
description: >
Anti-enterocyte and anti-goblet-cell antibodies can support the diagnosis,
although recent adult cohorts show that AIE can be diagnosed without
detectable anti-enterocyte antibodies when clinical and histologic criteria
are otherwise met.
cell_types:
- preferred_term: B cell
term:
id: CL:0000236
label: B cell
biological_processes:
- preferred_term: Humoral immune response
term:
id: GO:0006959
label: humoral immune response
evidence:
- reference: PMID:24045285
reference_title: "Abatacept: a new treatment option for refractory adult autoimmune enteropathy."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "presence of an anti-enterocyte and/or anti-goblet cell antibody supports the diagnosis and sometimes correlates with disease improvement, but is not required to make the diagnosis"
explanation: >
Full-text diagnostic criteria support anti-enterocyte and anti-goblet-cell
antibodies as adjunctive markers rather than absolute requirements.
- reference: PMID:38817655
reference_title: "Clinical manifestations, diagnosis and long-term prognosis of adult autoimmune enteropathy: Experience from Peking Union Medical College Hospital."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: "criteria due to undetectable anti-enterocyte antibodies."
explanation: >
This supports a limitation of antibody-based criteria in adult AIE,
showing that antibody negativity does not exclude the diagnosis.
histopathology:
- name: Villous Blunting
frequency: OBLIGATE
diagnostic: true
context: Duodenal biopsies in adult autoimmune enteropathy
description: >
Duodenal biopsies in the adult AIE cohort showed villous blunting in all
evaluated patients.
evidence:
- reference: PMID:38817655
reference_title: "Clinical manifestations, diagnosis and long-term prognosis of adult autoimmune enteropathy: Experience from Peking Union Medical College Hospital."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Villous blunting (100%), deep crypt lymphocytic infiltration (67%), apoptotic bodies (50%), and mild intraepithelial lymphocytosis (69%) were observed in the duodenal biopsies."
explanation: >
Provides the exact quantitative frequency for villous blunting and other
duodenal microscopic findings in adult AIE.
- name: Deep Crypt Lymphocytic Infiltration
frequency: FREQUENT
diagnostic: true
context: Duodenal biopsies in adult autoimmune enteropathy
description: >
Deep crypt lymphocytic infiltration is a characteristic small-bowel biopsy
finding, present in two thirds of the adult cohort.
evidence:
- reference: PMID:38817655
reference_title: "Clinical manifestations, diagnosis and long-term prognosis of adult autoimmune enteropathy: Experience from Peking Union Medical College Hospital."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Villous blunting (100%), deep crypt lymphocytic infiltration (67%), apoptotic bodies (50%), and mild intraepithelial lymphocytosis (69%) were observed in the duodenal biopsies."
explanation: >
Quantifies deep crypt lymphocytic infiltration in duodenal biopsies.
- name: Goblet and Paneth Cell Loss
frequency: VERY_FREQUENT
diagnostic: true
context: Duodenum and ileum in adult autoimmune enteropathy
description: >
Reduced or absent goblet cells and Paneth cells are prominent epithelial
lineage abnormalities in adult AIE, especially in the duodenum.
evidence:
- reference: PMID:38817655
reference_title: "Clinical manifestations, diagnosis and long-term prognosis of adult autoimmune enteropathy: Experience from Peking Union Medical College Hospital."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "other remarkable abnormalities, including reduced or absent goblet cells (duodenum 94%, ileum 62%), reduced or absent Paneth cells (duodenum 94%, ileum 69%)"
explanation: >
Quantifies goblet-cell and Paneth-cell loss by intestinal site.
- name: Neutrophilic Infiltration
frequency: OBLIGATE
context: Duodenal biopsies in adult autoimmune enteropathy
description: >
Neutrophil infiltration was present in all duodenal biopsies in the adult
AIE cohort and in most ileal biopsies.
evidence:
- reference: PMID:38817655
reference_title: "Clinical manifestations, diagnosis and long-term prognosis of adult autoimmune enteropathy: Experience from Peking Union Medical College Hospital."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "69%) and neutrophil infiltration (duodenum 100%, ileum 69%)."
explanation: >
Provides exact quantitative support for neutrophilic infiltration in
duodenum and ileum.
phenotypes:
- name: Chronic Diarrhea
category: Gastrointestinal
frequency: VERY_FREQUENT
phenotype_term:
preferred_term: Chronic diarrhea
term:
id: HP:0002028
label: Chronic diarrhea
temporality: CHRONIC
evidence:
- reference: PMID:40317016
reference_title: "Comprehensive insights into pathogenesis, diagnosis, treatment, and prognosis in adult autoimmune enteropathy."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "chiefly chronic diarrhea."
explanation: >
Review abstract identifies chronic diarrhea as the chief gastrointestinal
manifestation of AIE.
- name: Secretory Diarrhea
category: Gastrointestinal
phenotype_term:
preferred_term: Secretory diarrhea
term:
id: HP:0002014
label: Diarrhea
temporality: CHRONIC
evidence:
- reference: PMID:38817655
reference_title: "Clinical manifestations, diagnosis and long-term prognosis of adult autoimmune enteropathy: Experience from Peking Union Medical College Hospital."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Diarrhea in AIE patients was characterized by secretory diarrhea."
explanation: >
Adult cohort characterizes the diarrhea subtype as secretory.
- name: Malabsorption
category: Gastrointestinal
phenotype_term:
preferred_term: Malabsorption
term:
id: HP:0002024
label: Malabsorption
evidence:
- reference: PMID:24045285
reference_title: "Abatacept: a new treatment option for refractory adult autoimmune enteropathy."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The diagnostic criteria for AIE has been updated since 1982, and now requires all of the following (A to D): (A) chronic diarrhea (> 6 weeks duration), (B) malabsorption, (C) small bowel histology showing partial or complete villous blunting, deep crypt lymphocytosis, increased apoptotic bodies, minimal intra-epithelial lymphocytosis, and (D) exclusion of other causes of villous atrophy including celiac disease, refractory sprue, and intestinal lymphoma"
explanation: >
Diagnostic criteria include malabsorption together with chronic diarrhea
and characteristic small-bowel histology.
- name: Weight Loss
category: Growth
phenotype_term:
preferred_term: Weight loss
term:
id: HP:0001824
label: Weight loss
evidence:
- reference: PMID:24045285
reference_title: "Abatacept: a new treatment option for refractory adult autoimmune enteropathy."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Diarrhea associated with AIE can be quite debilitating, resulting in electrolyte disturbances, weight loss, and malabsorption, and often requiring the initiation of parenteral nutrition."
explanation: >
Review/case-report background directly links AIE-associated diarrhea to
weight loss and malabsorption.
- name: Hypokalemia
category: Metabolic
phenotype_term:
preferred_term: Hypokalemia
term:
id: HP:0002900
label: Hypokalemia
evidence:
- reference: PMID:37731560
reference_title: "Efficacy of abatacept treatment in a patient with enteropathy carrying a variant of unsignificance in CTLA4 gene: A case report."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: "Severe hypokalemia was detected during an examination."
explanation: >
Case-report evidence supports hypokalemia as a possible severe electrolyte
complication in immune-mediated enteropathy overlapping AIE.
genetic:
- name: FOXP3
gene_term:
preferred_term: FOXP3
term:
id: hgnc:6106
label: FOXP3
association: Causative in IPEX-associated syndromic autoimmune enteropathy
relationship_type: CAUSATIVE
variant_origin: GERMLINE
inheritance:
- name: X-linked recessive
evidence:
- reference: PMID:30443250
reference_title: "Clinical, Immunological, and Molecular Heterogeneity of 173 Patients With the Phenotype of Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked (IPEX) Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The Immune dysregulation, Polyendocrinopathy, Enteropathy, X-linked (IPEX) syndrome is a rare hemizygous disorder"
explanation: >
The cached review states both X-linked IPEX and hemizygous disease,
supporting X-linked recessive inheritance for FOXP3-associated AIE.
features: >
Inheritance pattern: X-linked recessive. FOXP3 variants cause IPEX, a
regulatory T-cell disorder in which severe enteropathy is a defining
feature.
evidence:
- reference: PMID:30443250
reference_title: "Clinical, Immunological, and Molecular Heterogeneity of 173 Patients With the Phenotype of Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked (IPEX) Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "were identified in 88 IPEX patients, 9 of which were not previously reported."
explanation: >
Large IPEX/IPEX-like cohort supports FOXP3 as a causal gene for the
syndromic immune dysregulation phenotype that includes enteropathy.
- name: CTLA4
gene_term:
preferred_term: CTLA4
term:
id: hgnc:2505
label: CTLA4
association: Causative or risk-associated in IPEX-like immune dysregulation with enteropathy
relationship_type: CAUSATIVE
variant_origin: GERMLINE
inheritance:
- name: Autosomal dominant
evidence:
- reference: PMID:30443250
reference_title: "Clinical, Immunological, and Molecular Heterogeneity of 173 Patients With the Phenotype of Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked (IPEX) Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "heterozygous mutation in CTLA4 resulting in CTLA4 haploinsufficiency, causing decreased capacity to mediate cell contact-dependent suppression"
explanation: >
Heterozygous CTLA4 haploinsufficiency supports an autosomal dominant
inheritance pattern.
features: >
Inheritance pattern: autosomal dominant. CTLA4 haploinsufficiency and
variants can produce immune dysregulation, CVID-like disease, and
enteropathy, with genotype-informed abatacept use in selected severe cases.
evidence:
- reference: PMID:30443250
reference_title: "Clinical, Immunological, and Molecular Heterogeneity of 173 Patients With the Phenotype of Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked (IPEX) Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Examples are mutations in CD25 or STAT5b, genes that code for molecules that are required for homeostasis, fitness and maintenance of Treg cells (32, 33) or heterozygous mutation in CTLA4 resulting in CTLA4 haploinsufficiency, causing decreased capacity to mediate cell contact-dependent suppression (34)."
explanation: >
Supports CTLA4 haploinsufficiency as an IPEX-like immune regulatory
defect that can involve enteropathy.
- reference: PMID:37731560
reference_title: "Efficacy of abatacept treatment in a patient with enteropathy carrying a variant of unsignificance in CTLA4 gene: A case report."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: "and LRBA variants were identified and abatacept treatment was initiated. With"
explanation: >
Case-level evidence links CTLA4/LRBA variants with immune-mediated
enteropathy and targeted abatacept use.
- name: LRBA
gene_term:
preferred_term: LRBA
term:
id: hgnc:1742
label: LRBA
association: Causative in LRBA-deficiency immune dysregulation with enteropathy
relationship_type: CAUSATIVE
variant_origin: GERMLINE
inheritance:
- name: Autosomal recessive
evidence:
- reference: PMID:30443250
reference_title: "Clinical, Immunological, and Molecular Heterogeneity of 173 Patients With the Phenotype of Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked (IPEX) Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "All mutations identified in LRBA are novel and homozygous, two being nonsense mutations and one causing a frameshift"
explanation: >
Homozygous loss-of-function LRBA variants support autosomal recessive
inheritance.
features: >
Inheritance pattern: autosomal recessive. LRBA deficiency is an IPEX-like
immune dysregulation disorder associated with early-onset enteropathy and
endocrinopathies.
evidence:
- reference: PMID:30443250
reference_title: "Clinical, Immunological, and Molecular Heterogeneity of 173 Patients With the Phenotype of Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked (IPEX) Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "More recently, mutations in LRBA have been reported as a cause of IPEX-like clinical manifestations characterized by early-onset enteropathy and endocrinopathies (35)."
explanation: >
Supports LRBA as a genetic cause of an IPEX-like syndrome with early-onset
enteropathy.
- name: STAT3
gene_term:
preferred_term: STAT3
term:
id: hgnc:11364
label: STAT3
association: Gain-of-function STAT3 variants can cause IPEX-like immune dysregulation with enteropathy
relationship_type: CAUSATIVE
variant_origin: GERMLINE
features: >
STAT3 gain-of-function variants are part of the genetically heterogeneous
IPEX-like immune dysregulation spectrum and can include enteropathy.
evidence:
- reference: PMID:30443250
reference_title: "Clinical, Immunological, and Molecular Heterogeneity of 173 Patients With the Phenotype of Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked (IPEX) Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "gain of function mutations (GOF) in STAT1 and STAT3"
explanation: >
Supports STAT3 gain-of-function as a genetic cause within the IPEX-like
immune dysregulation spectrum.
- reference: PMID:30443250
reference_title: "Clinical, Immunological, and Molecular Heterogeneity of 173 Patients With the Phenotype of Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked (IPEX) Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Among the IPEX-like cohort, patients with mutations in genes related to Treg function (i.e., CD25, STAT5b, STAT3 and STAT1 GOF, LRBA, CTLA4) are affected by a clinical phenotype strongly resembling IPEX."
explanation: >
Links STAT3 GOF to the IPEX-like phenotype that includes immune
dysregulation symptoms such as enteropathy.
treatments:
- name: Glucocorticoid Therapy
description: >
Systemic glucocorticoids are commonly used as initial immunosuppressive
therapy, with many adult patients responding clinically but requiring
maintenance immunosuppression or relapsing.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: prednisolone
term:
id: CHEBI:8378
label: prednisolone
target_phenotypes:
- preferred_term: Secretory diarrhea
term:
id: HP:0002014
label: Diarrhea
target_mechanisms:
- target: Mucosal Epithelial Injury
treatment_effect: MODULATES
description: Glucocorticoids suppress inflammatory mucosal injury and improve diarrhea in responsive patients.
evidence:
- reference: PMID:38817655
reference_title: "Clinical manifestations, diagnosis and long-term prognosis of adult autoimmune enteropathy: Experience from Peking Union Medical College Hospital."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "glucocorticoid therapy as the initial medication, of which 14/16 patients"
explanation: >
Adult cohort supports glucocorticoids as common initial therapy with
rapid clinical response in most patients.
- name: Steroid-Sparing Immunosuppression
description: >
Steroid-dependent or steroid-refractory AIE may require additional
immunosuppressants or biologics such as azathioprine, calcineurin
inhibitors, sirolimus, mycophenolate, rituximab, cyclophosphamide, or
anti-TNF therapy.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
target_phenotypes:
- preferred_term: Chronic diarrhea
term:
id: HP:0002028
label: Chronic diarrhea
target_mechanisms:
- target: FOXP3-Associated Treg Deficiency
treatment_effect: MODULATES
description: Steroid-sparing immunosuppressants reduce dysregulated immune activity in refractory or steroid-dependent disease.
- target: CTLA4 Checkpoint Dysfunction
treatment_effect: MODULATES
description: Immunosuppressants and biologics can reduce checkpoint-related dysregulated immune activity in selected IPEX-like disease.
- target: Mucosal Epithelial Injury
treatment_effect: MODULATES
description: Immunosuppression is used to control intestinal inflammation and maintain clinical response.
evidence:
- reference: PMID:24045285
reference_title: "Abatacept: a new treatment option for refractory adult autoimmune enteropathy."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Treatment options that have been reported include steroids, IV immunoglobulins (IVIG), azathioprine, budesonide, 6-mercaptopurine (6-MP), methotrexate, cyclosporine A, tacrolimus, sirolimus, mycophenolate mofetil, rituximab, cyclophosphamide, and anti-TNF inhibitors such as infliximab2-5,7,8."
explanation: >
Full-text treatment review/case report enumerates steroid-sparing
immunosuppressive options used in AIE.
- reference: PMID:38817655
reference_title: "Clinical manifestations, diagnosis and long-term prognosis of adult autoimmune enteropathy: Experience from Peking Union Medical College Hospital."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "administered to 9 patients with indications of steroid dependence (6/9), steroid"
explanation: >
Adult cohort supports use of additional immunosuppressants for steroid
dependence, refractory disease, or maintenance.
- name: Abatacept
description: >
CTLA4-Ig therapy can be considered in selected refractory or
CTLA4/LRBA-associated immune-mediated enteropathy, but current evidence is
case-report level.
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
target_phenotypes:
- preferred_term: Chronic diarrhea
term:
id: HP:0002028
label: Chronic diarrhea
target_mechanisms:
- target: CTLA4 Checkpoint Dysfunction
treatment_effect: MODULATES
description: Abatacept modulates T-cell activation through CTLA4-Ig costimulation blockade.
evidence:
- reference: PMID:24045285
reference_title: "Abatacept: a new treatment option for refractory adult autoimmune enteropathy."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: "multiple conventional therapies, she demonstrated clinical and histologic"
explanation: >
Case-report evidence supports abatacept for refractory adult AIE but is
not sufficient to generalize as standard therapy.
- reference: PMID:37731560
reference_title: "Efficacy of abatacept treatment in a patient with enteropathy carrying a variant of unsignificance in CTLA4 gene: A case report."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: "regressed, and there was an increase in weight."
explanation: >
Case-report evidence supports targeted abatacept therapy in immune-
mediated enteropathy with CTLA4/LRBA variants, with limited evidence
strength.
- name: Hematopoietic Stem Cell Transplantation
description: >
HSCT is a curative treatment consideration for severe IPEX and IPEX-like
immune dysregulation with enteropathy, with cohort evidence of post-
transplant resolution of enteropathy in most surviving patients and improved
survival.
treatment_term:
preferred_term: hematopoietic stem cell transplantation
term:
id: MAXO:0000747
label: hematopoietic stem cell transplantation
target_phenotypes:
- preferred_term: Chronic diarrhea
term:
id: HP:0002028
label: Chronic diarrhea
target_mechanisms:
- target: FOXP3-Associated Treg Deficiency
treatment_effect: MODULATES
description: HSCT can reconstitute immune regulation in severe IPEX.
- target: CTLA4 Checkpoint Dysfunction
treatment_effect: MODULATES
description: HSCT can be considered in severe IPEX-like immune dysregulation.
evidence:
- reference: PMID:30443250
reference_title: "Clinical, Immunological, and Molecular Heterogeneity of 173 Patients With the Phenotype of Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked (IPEX) Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Most surviving patients had resolution of their enteropathy and skin disease post-transplantation"
explanation: >
Cohort transplant outcomes support HSCT as a treatment for enteropathy in
IPEX and IPEX-like disease.
- reference: PMID:30443250
reference_title: "Clinical, Immunological, and Molecular Heterogeneity of 173 Patients With the Phenotype of Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked (IPEX) Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "HSCT improves the survival rate, supporting early HSCT as curative treatment"
explanation: >
Directly supports HSCT as curative treatment with survival benefit in the
IPEX/IPEX-like cohort.
- name: Nutritional and Supportive Care
description: >
Severe diarrhea and malabsorption may require supportive care, including
correction of electrolyte abnormalities and parenteral nutrition.
treatment_term:
preferred_term: supportive care
term:
id: MAXO:0000950
label: supportive care
target_phenotypes:
- preferred_term: Malabsorption
term:
id: HP:0002024
label: Malabsorption
- preferred_term: Weight loss
term:
id: HP:0001824
label: Weight loss
evidence:
- reference: PMID:24045285
reference_title: "Abatacept: a new treatment option for refractory adult autoimmune enteropathy."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Diarrhea associated with AIE can be quite debilitating, resulting in electrolyte disturbances, weight loss, and malabsorption, and often requiring the initiation of parenteral nutrition."
explanation: >
Supports nutritional and electrolyte support for severe AIE-associated
diarrhea and malabsorption.
clinical_trials:
- name: NCT04280510
phase: NOT_APPLICABLE
status: RECRUITING
description: >
Observational study of mechanisms underlying adult immune enteropathies,
including autoimmune enteropathy, with immune and intestinal-homeostasis
endpoints.
target_phenotypes:
- preferred_term: Chronic diarrhea
term:
id: HP:0002028
label: Chronic diarrhea
evidence:
- reference: clinicaltrials:NCT04280510
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The study focuses the mechanisms underlying the loss of intestinal homeostasis in celiac disease, refractory celiac disease and other immune diseases such as monogenic enteropathy, inflammatory bowel diseases or drug induced intestinal diseases."
explanation: >
ClinicalTrials.gov summary supports an observational immune-enteropathy
mechanism study relevant to AIE biology.
- name: NCT03866538
phase: PHASE_IV
status: TERMINATED
description: >
Budesonide withdrawal trial in immune-mediated enteropathies including
autoimmune enteropathy; ClinicalTrials.gov currently reports termination.
target_phenotypes:
- preferred_term: Chronic diarrhea
term:
id: HP:0002028
label: Chronic diarrhea
evidence:
- reference: clinicaltrials:NCT03866538
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Researchers are trying to determine if withdrawal of budesonide therapy in patients with immune-mediated enteropathies doing well on therapy will result in worsening symptoms, histology, quality of life, and micronutrient/nutritional status when compared to continued therapy."
explanation: >
Trial summary documents a budesonide-withdrawal study for immune-mediated
enteropathies, a group including AIE.
- name: NCT00258180
phase: PHASE_II
status: COMPLETED
description: >
Phase II study of high-dose cyclophosphamide for severe autoimmune
enteropathy in young patients.
target_phenotypes:
- preferred_term: Chronic diarrhea
term:
id: HP:0002028
label: Chronic diarrhea
evidence:
- reference: clinicaltrials:NCT00258180
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "PURPOSE: This phase II trial is studying how well cyclophosphamide works in treating young patients with severe autoimmune enteropathy."
explanation: >
ClinicalTrials.gov summary documents a completed phase II treatment trial
specifically for severe autoimmune enteropathy.
references:
- reference: PMID:38817655
title: "Clinical manifestations, diagnosis and long-term prognosis of adult autoimmune enteropathy: Experience from Peking Union Medical College Hospital."
findings: []
- reference: PMID:40317016
title: "Comprehensive insights into pathogenesis, diagnosis, treatment, and prognosis in adult autoimmune enteropathy."
findings: []
- reference: PMID:30443250
title: "Clinical, Immunological, and Molecular Heterogeneity of 173 Patients With the Phenotype of Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked (IPEX) Syndrome."
findings: []
- reference: PMID:24045285
title: "Abatacept: a new treatment option for refractory adult autoimmune enteropathy."
findings: []
- reference: PMID:37731560
title: "Efficacy of abatacept treatment in a patient with enteropathy carrying a variant of unsignificance in CTLA4 gene: A case report."
findings: []
- reference: clinicaltrials:NCT04280510
title: Pathogenic Study of Adult Immune Enteropathies
findings: []
- reference: clinicaltrials:NCT03866538
title: Open-label Withdrawal Trial of Budesonide in Patients With Immune Mediated Enteropathies
findings: []
- reference: clinicaltrials:NCT00258180
title: High-Dose Cyclophosphamide for the Treatment of Severe Autoimmune Enteropathy
findings: []
Autoimmune enteropathy (AIE) is a rare immune-mediated enteropathy defined by chronic/protracted diarrhea with malabsorption and characteristic small-intestinal mucosal injury (villous blunting/atrophy with crypt injury), after exclusion of more common causes of villous atrophy such as celiac disease and infection (shihaz2022autoimmuneenteropathyin pages 1-6, gentile2012autoimmuneenteropathya pages 2-4, umetsu2018autoimmuneenteropathies pages 1-2). Contemporary adult cohorts emphasize that AIE often presents as secretory, high-volume watery diarrhea with severe nutritional consequences and frequent need for corticosteroids and steroid-sparing immunosuppression, yet long-term outcomes remain unsatisfactory with substantial relapse risk (li2024clinicalmanifestationsdiagnosis pages 9-11, li2025comprehensiveinsightsinto pages 3-4).
A key recent development (2024) is a 16-patient adult cohort from Peking Union Medical College Hospital that quantified histopathology and outcomes and highlighted goblet/Paneth cell depletion and neutrophilic crypt injury as potentially useful diagnostic clues in adults, especially when anti-enterocyte antibodies are undetectable (li2024clinicalmanifestationsdiagnosis pages 9-11, li2024clinicalmanifestationsdiagnosis media 05afd713, li2024clinicalmanifestationsdiagnosis media ec9b1a39). A second recent development (2023–2025) is the growing use of genotype-informed diagnosis and targeted therapy in immune dysregulation syndromes that can manifest as AIE (e.g., CTLA4/LRBA with abatacept; STAT3 gain-of-function with pathway-directed therapy), supported by expanding sequencing-based yields in “AIE” case series and IPEX/IPEX-like cohorts (li2025comprehensiveinsightsinto pages 1-2, gambineri2018clinicalimmunologicaland pages 1-2).
AIE is described as “an uncommon to rare clinical entity characterized by intractable diarrhoea, varying levels of villous atrophy of the small intestine, [and] presence of circulating auto antibodies to enterocytes” (quote) (shihaz2022autoimmuneenteropathyin pages 1-6). It is considered among the major differentials of seronegative villous atrophy and refractory diarrhea and may involve small bowel predominantly, but gastric and colonic involvement can occur (shihaz2022autoimmuneenteropathyin pages 1-6, shihaz2022autoimmuneenteropathyin pages 6-10).
The evidence in this report is derived from aggregated disease-level resources (reviews and cohorts) and individual case reports, rather than EHR-only sources (gentile2012autoimmuneenteropathya pages 2-4, li2024clinicalmanifestationsdiagnosis pages 9-11, li2025comprehensiveinsightsinto pages 3-4).
AIE is heterogeneous. A major etiologic theme is immune dysregulation with loss of tolerance at the intestinal mucosa; monogenic immune regulatory disorders frequently manifest with “AIE-like” enteropathy, especially with early onset (umetsu2018autoimmuneenteropathies pages 1-2, chen2020areviewof pages 2-4, gambineri2018clinicalimmunologicaland pages 1-2).
A recent adult AIE synthesis states (abstract quote): “Pathogenesis might involve genetic predisposition, aberrant immune homeostasis, comorbidities of autoimmune diseases and environmental trigger.” (li2025comprehensiveinsightsinto pages 1-2).
Genetic / syndromic risk factors (primary immune regulatory disorders): * FOXP3 (IPEX syndrome, X-linked): IPEX is a prototypic syndromic cause; FOXP3 encodes a transcription factor required for thymus-derived regulatory T cells (Tregs), and “tTreg cell dysfunction is the main pathogenic event” (abstract quote) (arienzo2025paediatriccongenitalenteropathies pages 8-10, gambineri2018clinicalimmunologicaland pages 1-2). A review of AIE-associated syndromes notes “to date, over 70 mutations have been identified in the FOXP3 gene” (chen2020areviewof pages 2-4). * CTLA4 haploinsufficiency (dominant) and LRBA deficiency (recessive): LRBA deficiency presents with immune dysregulation/enteropathy and overlaps clinically with CTLA4 haploinsufficiency; LRBA impacts CTLA-4 biology (chen2020areviewof pages 2-4). In a 26-patient Tregopathy series, LRBA was the most frequent diagnosis (13/26), with CTLA4 defects in 5/26 (iyengar2025tregopathyinfocus pages 5-7). * STAT3 gain-of-function (GOF): A 2023 review describes STAT3-GOF as a multi-organ immune regulatory disorder and lists enteropathy among manifestations (abstract quote: “disease … can encompass a wide range of clinical manifestations such as: enteropathy…”) (shihaz2022autoimmuneenteropathyin pages 6-10). * AIRE (APECED/APS-1): APECED is a monogenic central tolerance disorder; GI/enteropathy can be part of the phenotype, and autoantibodies linked to GI dysfunction (e.g., TPH antibodies) are reported (enache2025diagnosticchallengesin pages 8-10).
Comorbid immunodeficiency/autoimmunity: AIE often co-occurs with other autoimmune disease and immunodeficiency (e.g., CVID). One adult review reports ~18% concurrent CVID and ~80% predisposition to autoimmunity (shihaz2022autoimmuneenteropathyin pages 1-6).
No specific protective genetic or environmental factors were identified in the retrieved evidence.
Direct gene–environment interaction evidence was not identified in the retrieved corpus; however, reviews acknowledge possible “environmental trigger” in adult AIE pathogenesis (li2025comprehensiveinsightsinto pages 1-2).
Across cohorts and reviews, the dominant phenotype is chronic, profuse watery diarrhea with malabsorption and marked nutritional impact (shihaz2022autoimmuneenteropathyin pages 1-6, umetsu2018autoimmuneenteropathies pages 1-2, li2025comprehensiveinsightsinto pages 3-4).
Adult quantitative phenotype (case-review of 208 adults): * Stool frequency ≥10/day in 83%; daily volume up to 1,000–10,000 mL (li2025comprehensiveinsightsinto pages 3-4). * Median weight loss 16.0 kg (IQR 10.0–25.8) (li2025comprehensiveinsightsinto pages 3-4). * Gluten-free diet ineffective in 86% of tested cases (li2025comprehensiveinsightsinto pages 3-4).
Adult cohort phenotype (Peking cohort, 2011–2023; n=16): * Diarrhea described as secretory diarrhea (li2024clinicalmanifestationsdiagnosis pages 9-11).
Pediatric phenotype: Pediatric AIE most commonly presents in infancy (often within first 6 months) with severe/intractable diarrhea and failure to thrive (umetsu2018autoimmuneenteropathies pages 1-2). A review of AIE and transplant highlights that pediatric diarrhea may be extremely voluminous (reported up to ~5000 mL/day) and is often non-bloody; electrolyte abnormalities and inability to tolerate feeds are common and parenteral nutrition may be required (ahmed2019autoimmuneenteropathyan pages 1-2).
AIE frequently occurs with extra-intestinal autoimmune disease, particularly in syndromic/monogenic contexts (umetsu2018autoimmuneenteropathies pages 1-2, gentile2012autoimmuneenteropathya pages 1-2). Examples include endocrinopathies (type 1 diabetes, thyroiditis), autoimmune hepatitis, hematologic autoimmunity, and renal disease (umetsu2018autoimmuneenteropathies pages 1-2, gentile2012autoimmuneenteropathya pages 1-2).
In a 40-patient AIE cohort (age 2 months–73 years), onset was “uniformly with secretory-type diarrhea” and multiple immune/autoimmune comorbidities were reported (e.g., CVID/hypogammaglobulinemia, uveitis, hepatitis, cholangitis, adrenal insufficiency, glomerulopathy) (villanacci2019clinicalmanifestationsand pages 2-3).
Adult reviews report nutritional and systemic abnormalities such as fat-soluble vitamin deficiencies (up to 90%), elevated transaminases (up to 67%), and mild hypogammaglobulinemia (up to 33%) (shihaz2022autoimmuneenteropathyin pages 6-10).
(These term IDs are provided as ontology suggestions; confirm exact IDs against the HPO release used by your knowledge base.)
A recent adult AIE review reported that genetic screening found pathogenic variants in 20/48 (41.6%) AIE patients, including CTLA4, STAT3, LRBA, STAT1 and others (li2025comprehensiveinsightsinto pages 1-2). This supports an emerging practice: when adult AIE is diagnosed (especially with systemic features), targeted panels or exome sequencing can identify actionable immune regulatory disorders (li2025comprehensiveinsightsinto pages 1-2).
Detailed variant-by-variant classification (ACMG pathogenicity, allele frequency in gnomAD, etc.) was not extractable from the retrieved evidence; the cohort evidence above supports that diverse variant classes exist across immune regulatory genes (gambineri2018clinicalimmunologicaland pages 1-2).
(Confirm term IDs against the versions used in your ontology pipeline.)
No robust environmental toxin/lifestyle/infectious triggers were identified as causal from the retrieved corpus; infectious causes are primarily part of the differential diagnosis and are typically excluded in AIE workups (ahmed2019autoimmuneenteropathyan pages 1-2, gentile2012autoimmuneenteropathya pages 1-2).
AIE is thought to arise from breakdown of immune tolerance at the intestinal mucosa, often involving defective regulatory pathways (FOXP3/Tregs; CTLA4 checkpoint function; LRBA-mediated CTLA4 trafficking), leading to dysregulated effector immune responses and epithelial injury (chen2020areviewof pages 2-4, gambineri2018clinicalimmunologicaland pages 1-2, iyengar2025tregopathyinfocus pages 5-7). The histologic consequence is villous blunting/atrophy with crypt injury and apoptosis, accompanied by mucosal inflammation; goblet and Paneth cell depletion are often observed (gentile2012autoimmuneenteropathya pages 2-4, li2024clinicalmanifestationsdiagnosis pages 9-11).
Primary involvement is the small intestine (duodenum/ileum often biopsied), with possible stomach and colon involvement (shihaz2022autoimmuneenteropathyin pages 1-6, shihaz2022autoimmuneenteropathyin pages 6-10). Endoscopic abnormalities include edema, villous blunting, mucosal hyperemia in duodenum/ileum (li2024clinicalmanifestationsdiagnosis pages 9-11).
The key target tissue is intestinal mucosa/epithelium, with enterocyte injury and crypt apoptosis; goblet and Paneth cell depletion is frequent (li2024clinicalmanifestationsdiagnosis pages 9-11).
UBERON suggestions (examples): small intestine (UBERON:0002108), duodenum (UBERON:0002114), ileum (UBERON:0002116), intestinal epithelium.
Course can be chronic and relapsing. In a 16-patient adult cohort, relapse-free survival declined over time: 62.5% (6 months), 55.6% (12 months), 37.0% (48 months) (li2024clinicalmanifestationsdiagnosis pages 9-11).
AIE is extremely rare; pediatric incidence is estimated at <1/100,000 (umetsu2018autoimmuneenteropathies pages 1-2). Precise adult prevalence is not established.
AIE diagnostic criteria historically included protracted diarrhea refractory to diet, autoimmunity/autoantibodies, and absence of severe immunodeficiency (shihaz2022autoimmuneenteropathyin pages 1-6, villanacci2019clinicalmanifestationsand pages 1-2). A 2024 adult cohort notes that diagnosis was based on “the 2007 diagnostic criteria” and discusses later iterations (2018, 2022) with emphasis on histology and supporting features (li2024clinicalmanifestationsdiagnosis pages 9-11).
AIE histology often features villous atrophy/blunting with crypt injury (crypt lymphocytosis, apoptotic bodies), relative paucity of surface IELs (compared with classic celiac), and goblet/Paneth cell loss (gentile2012autoimmuneenteropathya pages 2-4, li2024clinicalmanifestationsdiagnosis pages 9-11).
Adult cohort quantitative histology (Li 2024, n=16): * Villous blunting 100% * Deep crypt lymphocytic infiltration 67% * Apoptotic bodies 50% * Mild intraepithelial lymphocytosis 69% * Reduced/absent goblet cells (duodenum) 94% * Reduced/absent Paneth cells (duodenum) 94% * Neutrophil infiltration (duodenum) 100% (li2024clinicalmanifestationsdiagnosis pages 9-11)
Figure/Table evidence from this paper includes a table of diagnostic criteria and a figure summarizing histopathology frequencies (li2024clinicalmanifestationsdiagnosis media 05afd713, li2024clinicalmanifestationsdiagnosis media ec9b1a39).
Anti-enterocyte and anti-goblet cell antibodies are considered supportive but imperfect; sensitivity/specificity are incompletely defined and positivity can occur in other conditions (IBD, HIV, allergic enteropathy, celiac disease) (gentile2012autoimmuneenteropathya pages 2-4, enache2025diagnosticchallengesin pages 8-10).
Adult AIE case-review (208 adults): AE antibody positive 52%, AG antibody positive 13% (li2025comprehensiveinsightsinto pages 3-4).
Major differentials include: * Celiac disease (including seronegative or refractory forms) * CVID enteropathy / immunodeficiency-associated enteropathy * Drug-induced immune-mediated enteropathy (e.g., checkpoint inhibitor injury) * Infectious enteritis * GVHD-like injury patterns (particularly in transplant settings) (umetsu2018autoimmuneenteropathies pages 1-2)
Given overlap with IPEX-like disorders and meaningful therapeutic implications (e.g., abatacept for CTLA4/LRBA defects), next-generation sequencing panels or exome sequencing are increasingly relevant when AIE is severe, early-onset, refractory, or accompanied by multi-system autoimmunity/immunodeficiency (li2025comprehensiveinsightsinto pages 1-2, gambineri2018clinicalimmunologicaland pages 1-2).
Robust prognostic biomarkers were not definitively extractable from the retrieved evidence, although the adult cohort suggested that certain histopathologic features (e.g., goblet/Paneth cell depletion) may have diagnostic/prognostic relevance (li2024clinicalmanifestationsdiagnosis pages 9-11).
Corticosteroids are a common first-line therapy (shihaz2022autoimmuneenteropathyin pages 1-6, gentile2012autoimmuneenteropathya pages 1-2). In the 16-patient adult cohort, “All patients received glucocorticoid therapy as the initial medication,” and 14/16 achieved clinical response in a median of 5 days (IQR 3–20) (abstract quote) (li2024clinicalmanifestationsdiagnosis pages 9-11). Immunosuppressants are commonly added for steroid dependence or refractory disease (li2024clinicalmanifestationsdiagnosis pages 9-11, shihaz2022autoimmuneenteropathyin pages 6-10).
MAXO suggestions (examples): systemic glucocorticoid therapy; immunosuppressive agent therapy; total parenteral nutrition.
Abatacept (CTLA4-Ig): A 2023 case report describes a patient with immune-mediated enteropathy with CTLA4/LRBA variants and reports rapid clinical and laboratory regression with abatacept, supporting CTLA4-pathway targeting in severe disease (shihaz2022autoimmuneenteropathyin pages 6-10).
HSCT: For IPEX and some severe immune dysregulation disorders, HSCT is described as the only known effective cure in classic IPEX-focused reviews (arienzo2025paediatriccongenitalenteropathies pages 8-10), and HSCT is discussed as definitive for IPEX-associated disease in AIE-oriented reviews (shihaz2022autoimmuneenteropathyin pages 6-10).
Severe malnutrition and need for parenteral nutrition are common, especially in severe pediatric disease and in adult cases with high-volume secretory diarrhea (ahmed2019autoimmuneenteropathyan pages 1-2, umetsu2018autoimmuneenteropathies pages 1-2, li2025comprehensiveinsightsinto pages 3-4).
No established primary prevention strategies are identified; emphasis is on early recognition in high-risk contexts (early-onset polyautoimmunity, immunodeficiency, refractory villous atrophy) and timely genetic diagnosis to enable targeted treatment (li2025comprehensiveinsightsinto pages 1-2, gambineri2018clinicalimmunologicaland pages 1-2).
No naturally occurring animal disease analogs were identified in the retrieved evidence corpus.
Classic mechanistic inference frequently references the scurfy mouse model (Foxp3 deficiency) as an immune dysregulation model relevant to IPEX-like enteropathy (gambineri2018clinicalimmunologicaland pages 1-2). Detailed model organism phenotype mapping was not available in the retrieved excerpts.
Li et al. (World Journal of Gastroenterology; May 2024) provide updated adult AIE histology quantitation and outcomes. Their abstract highlights frequent goblet and Paneth cell depletion and notes that patients “fulfilled the 2018 diagnostic criteria but did not match the 2022 diagnostic criteria due to undetectable anti-enterocyte antibodies,” supporting a pragmatic, histology-forward diagnostic approach when serology is negative (li2024clinicalmanifestationsdiagnosis pages 9-11). This paper’s Table/Figure summary is available in extracted images (li2024clinicalmanifestationsdiagnosis media 05afd713, li2024clinicalmanifestationsdiagnosis media ec9b1a39).
A 2023 case report of abatacept in immune-mediated enteropathy with CTLA4/LRBA variants argues for early consideration of abatacept in severe disease pending further testing (shihaz2022autoimmuneenteropathyin pages 6-10). While case-report evidence is low-level, it aligns with the increasingly accepted paradigm that “genetic diagnosis guides treatment” in immune dysregulation-associated enteropathies (concept supported by the adult AIE genetics review and IPEX-like cohorts) (li2025comprehensiveinsightsinto pages 1-2, gambineri2018clinicalimmunologicaland pages 1-2).
A Frontiers in Immunology 2023 cohort of pediatric APECED patients with GI manifestations notes that expanded diagnostic criteria could allow earlier recognition when non-endocrine manifestations (including gastro-enteropathy) appear early, emphasizing the need to consider autoimmune enteropathy within broader immune dysregulation syndromes (shihaz2022autoimmuneenteropathyin pages 6-10).
| Domain | Key points | Quantitative data (if any) | Key sources (first author year journal) | URL |
|---|---|---|---|---|
| Definition | Autoimmune enteropathy (AIE) is a rare immune-mediated enteropathy characterized by chronic/intractable diarrhea, malabsorption, and small-intestinal villous injury; it affects children and adults and may occur as isolated disease or in syndromic/monogenic immune dysregulation. (shihaz2022autoimmuneenteropathyin pages 1-6, umetsu2018autoimmuneenteropathies pages 1-2) | Pediatric incidence estimated <1/100,000 in one review. (umetsu2018autoimmuneenteropathies pages 1-2) | Shihaz 2022 Adv Dig Med; Umetsu 2018 Virchows Arch | https://doi.org/10.1002/aid2.13234 ; https://doi.org/10.1007/s00428-017-2243-7 |
| Diagnosis | Core adult diagnostic framework emphasizes chronic diarrhea (>6 weeks), malabsorption, characteristic small-bowel histology, and exclusion of other causes of villous atrophy; anti-enterocyte/anti-goblet cell antibodies are supportive rather than required. Earlier pediatric criteria included severe diarrhea refractory to exclusion diet, autoimmunity/autoantibodies, and absence of severe immunodeficiency. (shihaz2022autoimmuneenteropathyin pages 6-10, umetsu2018autoimmuneenteropathies pages 1-2, li2024clinicalmanifestationsdiagnosis pages 9-11, villanacci2019clinicalmanifestationsand pages 1-2) | Adult median age at diagnosis reported as 55 years in one series/review. (shihaz2022autoimmuneenteropathyin pages 1-6, umetsu2018autoimmuneenteropathies pages 1-2) | Shihaz 2022 Adv Dig Med; Umetsu 2018 Virchows Arch; Li 2024 World J Gastroenterol; Villanacci 2019 Clin Immunol | https://doi.org/10.1002/aid2.13234 ; https://doi.org/10.1007/s00428-017-2243-7 ; https://doi.org/10.3748/wjg.v30.i19.2523 ; https://doi.org/10.1016/j.clim.2019.07.001 |
| Histology | Key histopathology includes villous blunting/atrophy, crypt hyperplasia, deep crypt lymphocytic infiltration, increased crypt apoptotic bodies, mononuclear lamina propria inflammation, and frequent goblet- and Paneth-cell loss; surface intraepithelial lymphocytosis is often only mild/minimal. Histologic patterns may mimic celiac disease, chronic active duodenitis, GVHD, or mixed injury. (gentile2012autoimmuneenteropathya pages 2-4, arienzo2025paediatriccongenitalenteropathies pages 8-10, li2024clinicalmanifestationsdiagnosis pages 9-11, villanacci2019clinicalmanifestationsand pages 1-2) | In the Peking cohort (n=16 adults), duodenal biopsy showed villous blunting 100%, deep crypt lymphocytic infiltration 67%, apoptotic bodies 50%, mild IEL increase 69%, reduced/absent goblet cells 94%, reduced/absent Paneth cells 94%, neutrophil infiltration 100%; ileal goblet-cell loss 62%, Paneth-cell loss 69%. In the 40-patient series, histologic patterns were celiac-like 50%, mixed 35%, chronic active duodenitis 10%, GVHD-like 5%. (li2024clinicalmanifestationsdiagnosis pages 9-11, villanacci2019clinicalmanifestationsand pages 1-2) | Li 2024 World J Gastroenterol; Gentile 2012 Curr Gastroenterol Rep; Villanacci 2019 Clin Immunol | https://doi.org/10.3748/wjg.v30.i19.2523 ; https://doi.org/10.1007/s11894-012-0276-2 ; https://doi.org/10.1016/j.clim.2019.07.001 |
| Autoantibodies | Anti-enterocyte (AEA/AE) and anti-goblet cell (AGA/AG) antibodies are helpful adjuncts but are neither sufficiently sensitive nor specific to establish diagnosis alone; they can also occur in IBD, HIV, allergic enteropathy, celiac disease, and CVID-associated enteropathy. (shihaz2022autoimmuneenteropathyin pages 6-10, gentile2012autoimmuneenteropathya pages 2-4, enache2025diagnosticchallengesin pages 8-10) | Reviews report AEA/AGA in 50% to >90% of cases; one review cites AEA in 22/26 (85%) and 13/15 (87%) cohorts, while another notes isolated AIE AEA positivity around 80–90% but nonspecific. (shihaz2022autoimmuneenteropathyin pages 1-6, gentile2012autoimmuneenteropathya pages 2-4, enache2025diagnosticchallengesin pages 8-10) | Gentile 2012 Curr Gastroenterol Rep; Shihaz 2022 Adv Dig Med; Enache 2025 Diagnostics | https://doi.org/10.1007/s11894-012-0276-2 ; https://doi.org/10.1002/aid2.13234 ; https://doi.org/10.3390/diagnostics15121511 |
| Genetics | AIE can be syndromic/monogenic, especially in early-onset disease. Established associations include FOXP3 (IPEX, X-linked), LRBA deficiency (autosomal recessive), CTLA4 haploinsufficiency (autosomal dominant), STAT3 gain-of-function, and AIRE-related APECED/APS-1. Adult AIE also shows heterogeneous predisposition genes. (chen2020areviewof pages 2-4, li2025comprehensiveinsightsinto pages 1-2, gambineri2018patientswiththe pages 1-2, gambineri2018clinicalimmunologicaland pages 1-2) | In a 173-patient IPEX/IPEX-like cohort, 44 distinct FOXP3 variants were found in 88 IPEX patients (including 9 novel variants), and 19 disease-associated variants in 9 genes were identified among 85 FOXP3-wild-type IPEX-like patients. In an adult AIE review, pathogenic variants were reported in 20/48 (41.6%) genetically screened patients. (li2025comprehensiveinsightsinto pages 1-2, gambineri2018clinicalimmunologicaland pages 1-2) | Gambineri 2018 Front Immunol; Li 2025 Orphanet J Rare Dis; Chen 2020 Dig Dis Sci | https://doi.org/10.3389/fimmu.2018.02411 ; https://doi.org/10.1186/s13023-025-03731-2 ; https://doi.org/10.1007/s10620-020-06540-8 |
| Mechanism | Central mechanism is loss of immune tolerance, especially defective regulatory T-cell (Treg) function. FOXP3 mutations impair Treg development/function; LRBA deficiency disrupts intracellular CTLA-4 trafficking/storage; CTLA4 haploinsufficiency reduces cell-contact–dependent suppression; STAT3 GOF promotes immune dysregulation/autoimmunity; these converge on mucosal immune activation, epithelial apoptosis, and enterocyte loss. (chen2020areviewof pages 2-4, gambineri2018patientswiththe pages 1-2, gambineri2018clinicalimmunologicaland pages 1-2, iyengar2025tregopathyinfocus pages 5-7) | FOXP3/IPEX median onset reported at 2 months, with 87% manifesting in the first year in one summarized cohort. (chen2020areviewof pages 2-4) | Gambineri 2018 Front Immunol; Chen 2020 Dig Dis Sci; Vogel 2023 Front Pediatr; Iyengar 2025 Front Immunol | https://doi.org/10.3389/fimmu.2018.02411 ; https://doi.org/10.1007/s10620-020-06540-8 ; https://doi.org/10.3389/fped.2022.770077 ; https://doi.org/10.3389/fimmu.2025.1658140 |
| Epidemiology | AIE is very rare and true prevalence/incidence in adults is not well defined. Adult disease is often diagnosed late and may overlap with primary immunodeficiency/CVID and other autoimmune disorders. (umetsu2018autoimmuneenteropathies pages 1-2, enache2025diagnosticchallengesin pages 8-10) | Pediatric incidence estimate <1/100,000; median symptom duration before diagnosis in one adult series/review was 1.5 years. (umetsu2018autoimmuneenteropathies pages 1-2) | Umetsu 2018 Virchows Arch; Enache 2025 Diagnostics | https://doi.org/10.1007/s00428-017-2243-7 ; https://doi.org/10.3390/diagnostics15121511 |
| Prognosis | Long-term outcomes remain suboptimal despite immunosuppression. Adult patients can relapse, require ongoing maintenance therapy/nutritional support, and may develop severe complications including multiorgan failure or lymphoma. (li2024clinicalmanifestationsdiagnosis pages 9-11) | In the 16-patient adult cohort, median follow-up was 20.5 months; 2/16 died of multiple organ failure and 1/16 developed non-Hodgkin lymphoma. Relapse-free survival was 62.5% at 6 months, 55.6% at 12 months, and 37.0% at 48 months. (li2024clinicalmanifestationsdiagnosis pages 9-11) | Li 2024 World J Gastroenterol | https://doi.org/10.3748/wjg.v30.i19.2523 |
| Treatment | First-line therapy is usually corticosteroids; steroid-sparing agents include azathioprine, tacrolimus/cyclosporine, sirolimus, and selected biologics/targeted agents such as abatacept for CTLA4/LRBA-related disease. Nutritional support, including TPN, is often necessary. HSCT is considered definitive for some severe monogenic forms (e.g., IPEX-like disorders). (shihaz2022autoimmuneenteropathyin pages 6-10, li2024clinicalmanifestationsdiagnosis pages 9-11, iyengar2025tregopathyinfocus pages 5-7) | In the Peking adult cohort, 14/16 responded clinically to initial glucocorticoids within median 5 days (IQR 3–20); 9/16 received immunosuppressants for steroid dependence/refractoriness or maintenance. Shihaz cites abnormal gastroscopy in ~58%, capsule endoscopy abnormalities in ~47%, fat-soluble vitamin deficiencies in up to 90%, and mild hypogammaglobulinemia up to 33%, supporting need for supportive care. In a 26-patient Tregopathy series, targeted therapy achieved complete control in 8/14 (57%) treated patients; 5 underwent HSCT and 4 were doing well. (shihaz2022autoimmuneenteropathyin pages 6-10, li2024clinicalmanifestationsdiagnosis pages 9-11, iyengar2025tregopathyinfocus pages 5-7) | Li 2024 World J Gastroenterol; Shihaz 2022 Adv Dig Med; Iyengar 2025 Front Immunol; Musabak 2023 World J Clin Cases | https://doi.org/10.3748/wjg.v30.i19.2523 ; https://doi.org/10.1002/aid2.13234 ; https://doi.org/10.3389/fimmu.2025.1658140 ; https://doi.org/10.12998/wjcc.v11.i26.6176 |
| Clinical trials | Current formal trial activity is limited. Ongoing observational work is studying pathogenesis of adult immune enteropathies with sequencing and immune profiling; a budesonide withdrawal trial in immune-mediated enteropathies was terminated for poor recruitment; an older phase II cyclophosphamide trial enrolled very few patients. (NCT04280510 chunk 1, NCT00258180 chunk 1, NCT03866538 chunk 1) | NCT04280510 recruiting observational cohort, target 200 adults, started 2020-02-27; NCT03866538 budesonide phase 4 trial terminated, actual enrollment 1; NCT00258180 phase II cyclophosphamide trial completed with actual enrollment 3. (NCT04280510 chunk 1, NCT00258180 chunk 1, NCT03866538 chunk 1) | ClinicalTrials.gov records NCT04280510, NCT03866538, NCT00258180 | https://clinicaltrials.gov/study/NCT04280510 ; https://clinicaltrials.gov/study/NCT03866538 ; https://clinicaltrials.gov/study/NCT00258180 |
Table: This table compiles evidence-backed facts about autoimmune enteropathy across definition, diagnosis, pathology, genetics, mechanism, prognosis, treatment, and ongoing clinical studies. It is formatted for direct use in a disease knowledge base and limited to sources retrieved in this conversation.
References
(shihaz2022autoimmuneenteropathyin pages 1-6): Ambalathu Veettil Hussain Shihaz and Jayanta Paul. Autoimmune enteropathy in adults. Advances in Digestive Medicine, 9:75-81, Oct 2022. URL: https://doi.org/10.1002/aid2.13234, doi:10.1002/aid2.13234. This article has 5 citations.
(gentile2012autoimmuneenteropathya pages 2-4): Nicole M. Gentile, Joseph A. Murray, and Darrell S. Pardi. Autoimmune enteropathy: a review and update of clinical management. Current Gastroenterology Reports, 14:380-385, Jul 2012. URL: https://doi.org/10.1007/s11894-012-0276-2, doi:10.1007/s11894-012-0276-2. This article has 161 citations.
(umetsu2018autoimmuneenteropathies pages 1-2): Sarah E. Umetsu, Ian Brown, Cord Langner, and Gregory Y. Lauwers. Autoimmune enteropathies. Virchows Archiv, 472:55-66, Oct 2018. URL: https://doi.org/10.1007/s00428-017-2243-7, doi:10.1007/s00428-017-2243-7. This article has 60 citations and is from a peer-reviewed journal.
(li2024clinicalmanifestationsdiagnosis pages 9-11): Mu-Han Li, Ge-Chong Ruan, Wei-Xun Zhou, Xiao-Qing Li, Sheng-Yu Zhang, Yang Chen, Xiao-Yin Bai, Hong Yang, Yu-Jie Zhang, Peng-Yu Zhao, Ji Li, and Jing-Nan Li. Clinical manifestations, diagnosis and long-term prognosis of adult autoimmune enteropathy: experience from peking union medical college hospital. World Journal of Gastroenterology, 30:2523-2537, May 2024. URL: https://doi.org/10.3748/wjg.v30.i19.2523, doi:10.3748/wjg.v30.i19.2523. This article has 7 citations.
(li2025comprehensiveinsightsinto pages 3-4): Muhan Li, Tianming Xu, Gechong Ruan, Chengzhu Ou, Bei Tan, Shengyu Zhang, Xiaoqing Li, Yan You, Weixun Zhou, Ji Li, and Jingnan Li. Comprehensive insights into pathogenesis, diagnosis, treatment, and prognosis in adult autoimmune enteropathy. Orphanet Journal of Rare Diseases, May 2025. URL: https://doi.org/10.1186/s13023-025-03731-2, doi:10.1186/s13023-025-03731-2. This article has 5 citations and is from a peer-reviewed journal.
(li2024clinicalmanifestationsdiagnosis media 05afd713): Mu-Han Li, Ge-Chong Ruan, Wei-Xun Zhou, Xiao-Qing Li, Sheng-Yu Zhang, Yang Chen, Xiao-Yin Bai, Hong Yang, Yu-Jie Zhang, Peng-Yu Zhao, Ji Li, and Jing-Nan Li. Clinical manifestations, diagnosis and long-term prognosis of adult autoimmune enteropathy: experience from peking union medical college hospital. World Journal of Gastroenterology, 30:2523-2537, May 2024. URL: https://doi.org/10.3748/wjg.v30.i19.2523, doi:10.3748/wjg.v30.i19.2523. This article has 7 citations.
(li2024clinicalmanifestationsdiagnosis media ec9b1a39): Mu-Han Li, Ge-Chong Ruan, Wei-Xun Zhou, Xiao-Qing Li, Sheng-Yu Zhang, Yang Chen, Xiao-Yin Bai, Hong Yang, Yu-Jie Zhang, Peng-Yu Zhao, Ji Li, and Jing-Nan Li. Clinical manifestations, diagnosis and long-term prognosis of adult autoimmune enteropathy: experience from peking union medical college hospital. World Journal of Gastroenterology, 30:2523-2537, May 2024. URL: https://doi.org/10.3748/wjg.v30.i19.2523, doi:10.3748/wjg.v30.i19.2523. This article has 7 citations.
(li2025comprehensiveinsightsinto pages 1-2): Muhan Li, Tianming Xu, Gechong Ruan, Chengzhu Ou, Bei Tan, Shengyu Zhang, Xiaoqing Li, Yan You, Weixun Zhou, Ji Li, and Jingnan Li. Comprehensive insights into pathogenesis, diagnosis, treatment, and prognosis in adult autoimmune enteropathy. Orphanet Journal of Rare Diseases, May 2025. URL: https://doi.org/10.1186/s13023-025-03731-2, doi:10.1186/s13023-025-03731-2. This article has 5 citations and is from a peer-reviewed journal.
(gambineri2018clinicalimmunologicaland pages 1-2): Eleonora Gambineri, Sara Ciullini Mannurita, David Hagin, Marina Vignoli, Stephanie Anover-Sombke, Stacey DeBoer, Gesmar R. S. Segundo, Eric J. Allenspach, Claudio Favre, Hans D. Ochs, and Troy R. Torgerson. Clinical, immunological, and molecular heterogeneity of 173 patients with the phenotype of immune dysregulation, polyendocrinopathy, enteropathy, x-linked (ipex) syndrome. Frontiers in Immunology, Nov 2018. URL: https://doi.org/10.3389/fimmu.2018.02411, doi:10.3389/fimmu.2018.02411. This article has 206 citations and is from a peer-reviewed journal.
(shihaz2022autoimmuneenteropathyin pages 6-10): Ambalathu Veettil Hussain Shihaz and Jayanta Paul. Autoimmune enteropathy in adults. Advances in Digestive Medicine, 9:75-81, Oct 2022. URL: https://doi.org/10.1002/aid2.13234, doi:10.1002/aid2.13234. This article has 5 citations.
(NCT04280510 chunk 1): Pathogenic Study of Adult Immune Enteropathies. Institut National de la Santé Et de la Recherche Médicale, France. 2020. ClinicalTrials.gov Identifier: NCT04280510
(NCT00258180 chunk 1): Cyclophosphamide in Treating Young Patients With Severe Autoimmune Enteropathy. Johns Hopkins University. 2005. ClinicalTrials.gov Identifier: NCT00258180
(chen2020areviewof pages 2-4): Charles B. Chen, Farah Tahboub, Thomas Plesec, Marsha Kay, and Kadakkal Radhakrishnan. A review of autoimmune enteropathy and its associated syndromes. Digestive Diseases and Sciences, 65:3079-3090, Aug 2020. URL: https://doi.org/10.1007/s10620-020-06540-8, doi:10.1007/s10620-020-06540-8. This article has 36 citations and is from a peer-reviewed journal.
(arienzo2025paediatriccongenitalenteropathies pages 8-10): Francesca Arienzo, Isabella Giovannoni, Antonella Diamanti, Chiara Maria Trovato, Paola De Angelis, Chiara Imondi, Rita Alaggio, and Paola Francalanci. Paediatric congenital enteropathies: clinical and histological review. Diagnostics, 15:946, Apr 2025. URL: https://doi.org/10.3390/diagnostics15080946, doi:10.3390/diagnostics15080946. This article has 1 citations.
(iyengar2025tregopathyinfocus pages 5-7): Vaishnavi Venkatachari Iyengar, Vijaya Gowri, Akshaya Sanjay Chougule, Prasad Taur, Manisha Rajan Madkaikar, Minnie Bodhanwala, and Mukesh Manharlal Desai. Tregopathy in focus. Frontiers in Immunology, Oct 2025. URL: https://doi.org/10.3389/fimmu.2025.1658140, doi:10.3389/fimmu.2025.1658140. This article has 2 citations and is from a peer-reviewed journal.
(enache2025diagnosticchallengesin pages 8-10): Iulia Enache, Ioan-Cristian Nedelcu, Marina Balaban, Daniel Vasile Balaban, Alina Popp, and Mariana Jinga. Diagnostic challenges in enteropathies: a histopathological review. Diagnostics, 15:1511, Jun 2025. URL: https://doi.org/10.3390/diagnostics15121511, doi:10.3390/diagnostics15121511. This article has 7 citations.
(ahmed2019autoimmuneenteropathyan pages 1-2): Zunirah Ahmed, Aamer Imdad, James A. Connelly, and Sari Acra. Autoimmune enteropathy: an updated review with special focus on stem cell transplant therapy. Digestive Diseases and Sciences, 64:643-654, Nov 2019. URL: https://doi.org/10.1007/s10620-018-5364-1, doi:10.1007/s10620-018-5364-1. This article has 49 citations and is from a peer-reviewed journal.
(gentile2012autoimmuneenteropathya pages 1-2): Nicole M. Gentile, Joseph A. Murray, and Darrell S. Pardi. Autoimmune enteropathy: a review and update of clinical management. Current Gastroenterology Reports, 14:380-385, Jul 2012. URL: https://doi.org/10.1007/s11894-012-0276-2, doi:10.1007/s11894-012-0276-2. This article has 161 citations.
(villanacci2019clinicalmanifestationsand pages 2-3): Vincenzo Villanacci, Vassilios Lougaris, Alberto Ravelli, Elisabetta Buscarini, Tiziana Salviato, Paolo Lionetti, Marianna Salemme, Stefano Martelossi, Costantino De Giacomo, Diego Falchetti, Gloria Pelizzo, and Gabrio Bassotti. Clinical manifestations and gastrointestinal pathology in 40 patients with autoimmune enteropathy. Clinical Immunology, 207:10-17, Oct 2019. URL: https://doi.org/10.1016/j.clim.2019.07.001, doi:10.1016/j.clim.2019.07.001. This article has 41 citations and is from a peer-reviewed journal.
(villanacci2019clinicalmanifestationsand pages 1-2): Vincenzo Villanacci, Vassilios Lougaris, Alberto Ravelli, Elisabetta Buscarini, Tiziana Salviato, Paolo Lionetti, Marianna Salemme, Stefano Martelossi, Costantino De Giacomo, Diego Falchetti, Gloria Pelizzo, and Gabrio Bassotti. Clinical manifestations and gastrointestinal pathology in 40 patients with autoimmune enteropathy. Clinical Immunology, 207:10-17, Oct 2019. URL: https://doi.org/10.1016/j.clim.2019.07.001, doi:10.1016/j.clim.2019.07.001. This article has 41 citations and is from a peer-reviewed journal.
(NCT03866538 chunk 1): Joseph A. Murray, M.D.. Budesonide in Patients With Immune Mediated Enteropathies. Mayo Clinic. 2019. ClinicalTrials.gov Identifier: NCT03866538
(gambineri2018patientswiththe pages 1-2): E Gambineri, SC Mannurita, and D Hagin. Patients with the phenotype of immune dysregulation, polyendocrinopathy, enteropathy, x-linked (ipex) syndrome. Unknown journal, 2018.